NEW YORK (GenomeWeb) – Bristol-Myers Squibb and Denmark's Nordic Bioscience have announced a collaboration to develop biomarkers to help diagnose and monitor scar-tissue related to diseases of the liver.

Under the terms of the agreement, the partners will develop biomarkers and diagnostics to evaluate non-alcoholic steatohepatitis (NASH) in pre-clinical models of fibrotic diseases and in clinical settings.

Nordic Bioscience brings to the collaboration experience developing assays using collagens, elastins, and laminins as biomarkers of the extracellular matrix.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.